このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

CBT on Fatigue in Survivors of Hodgkin Lymphoma

2021年4月27日 更新者:Anja Mehnert、University of Leipzig

Cognitive Behavioral Therapy (CBT) Web-based Intervention on Fatigue in Survivors of Hodgkin Lymphoma - a Pilot Study

Background: Cancer-related fatigue is one of the most common patient-reported impairments in survivors of Hodgkin lymphoma and is associated with adverse effects on psychological well-being and everyday life including family, work and social participation.

Methods: The investigators here present a bi-centric (Cologne and Leipzig) pilot-study for a web-based intervention (Cognitive Behavioral Therapy) on cancer-related fatigue. In detail, the investigators will conduct a non-randomized and non-controlled before-and-after study in a minimum of 20 survivors of Hodgkin lymphoma. Levels of fatigue and quality of life will be measured before the intervention (T0), post-intervention (T1) and at 3-months follow-up (T2).

Results: The investigators will provide information regarding the feasibility of the intervention (i.e., response rate, patient and therapist adherence, and patient satisfaction) and preliminary results on the efficacy of the program in reducing CRF and increasing levels of quality of life.

Aims: The results of this pilot-study will provide essential information to conduct a future randomized clinical trial to investigate the efficacy of this intervention in reducing cancer-related fatigue in survivors with Hodgkin lymphoma.

調査の概要

詳細な説明

Concrete Aims: The investigators aim to conduct a a feasibility study, e.g., a pilot study before a randomized controlled trial can be planned in detail. This initial pilot-study is intended to test out the standard operating procedures, evaluate the feasibility, acceptance and adherence to the study protocol as well as preliminary efficacy of the web-based intervention for survivors of Hodgkin lymphoma. In detail, this study contains all preparation for conducting a trial, i.e., the translation, the adaptation and evaluation of the cognitive-behavioral web-based intervention manual from the original Dutch Version, the adaptation and implementation of all necessary technical and research-administrative requirements to successfully conduct the web-based randomized controlled trial and the evidence-based training of all study therapists including the implementation of therapists supervision. The investigators further assess adherence of the patients and therapists, the response rate and the patient satisfaction. Furthermore, preliminary efficacy of the intervention will be tested assessing levels of fatigue and quality of life at each measurement point.

Study Design: The design of this pilot web-based intervention on treating fatigue will be a non-randomised prospective non-controlled before-and-after study, in which observations will be made only in a patient group that receives the intervention. No control group will be recruited. Assessments will be conducted on the three measurement points: before the therapy (T0), after the intervention (T1) and 3 months after the intervention (T2).

Intervention: The internet-based cognitive behavioral therapy on postcancer fatigue includes two face-to-face sessions with their therapist and eight web-based treatment modules, each approximately 45 minutes in length, delivered over 6 months. The intervention will be specifically tailored to the individual needs of each patient: The therapy model of cancer-related fatigue distinguishes six perpetuating factors: 1) insufficient processing of being diagnosed with Hodgkin lymphoma and being treated for it; 2) excessive fear of disease recurrence; 3) inactivity or a dysregulated (physical) activity pattern; 4) dysfunctional fatigue-related beliefs; 5) dysregulated sleep-wake pattern and 6) lack of social support. For each of these six cognitive-behavioural factors that can perpetuate fatigue a treatment module has been developed. The intervention will consist of a maximum of eight treatment modules: aside from the six modules addressing the fatigue maintaining factor there is a module on goal formulation and realization of goals.

Recruitment: the recruitment will be realized on the basis of two ongoing trials of the German Hodgkin study group (HD 16- HD18) where fatigue of the patients is measured continuously.

Duration: The duration for patients will be 9 months (6 months intervention, 3 month-follow-up assessment). The duration of the whole study will be 18 months.

研究の種類

介入

入学 (実際)

17

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Cologne、ドイツ
        • University Medical Center Cologne
    • Saxony
      • Leipzig、Saxony、ドイツ、04103
        • University Medical Center Leipzig

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • fluency in German language
  • able to access the internet and use and follow a web-based Cognitive Behavioral intervention
  • in complete remission after treatment for newly diagnosed HL without signs of relapse (no previous relapse)
  • clinically relevant fatigue symptoms enduring at least 12 months after end of treatment (QLQ-C30 FA-12 ≥ 30 over at least two time points within the previous assessments in the course of the GHSG-trials)
  • fatigue being related to HL and its treatment and interferes with usual functioning, i.e. fulfills the definition of CRF [1, 16].

Exclusion Criteria:

  • Major communication difficulties
  • severe cognitive impairment that would interfere with a patient's ability to give informed consent for research (indicated by the medical care team)
  • Karnofsky Performance Status scale score < 70 predicting an expected survival of less than 6 months
  • somatic co-morbidities that could explain the presence of severe fatigue (e.g. Chronic Obstructive Pulmonary Disease or heart failure) according to the hemato-oncologists examining the potential participant before inclusion for the study
  • history of relapsed or refractory HL
  • clinical symptoms which may indicate a relapse of HL
  • current depressive disorder and related psychotropic or psychological treatment
  • Currently receiving medical and/or psychological treatment for a psychiatric disorder, other than the use of an anti-depressant
  • current treatment aimed at fatigue
  • previous attempt to treat fatigue with behavioral psychological therapy
  • pregnant or breastfeeding women

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:支持療法
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Cognitive Behavioral Therapy for Treating Fatigue
This is the patient group that receives the intervention (IG), i.e., the cognitive behavioral therapy for reducing fatigue.

The internet-based CBT postcancer fatigue intervention includes two face-to-face sessions with their therapist and eight web-based treatment modules, each approximately 45 minutes in length, delivered over 6 months.

The intervention will be specifically tailored to the individual needs of each patient: The CBT model of cancer-related fatigue distinguishes six perpetuating factors: 1) insufficient processing of being diagnosed with HL and being treated for it; 2) excessive fear of disease recurrence; 3) inactivity or a dysregulated (physical) activity pattern; 4) dysfunctional fatigue-related beliefs; 5) dysregulated sleep-wake pattern and 6) lack of social support. For each of these six cognitive-behavioural factors that can perpetuate fatigue a treatment module has been developed.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
回答率
時間枠:この結果の評価期間は、募集開始から最後の患者が含まれるまでで、約 1 年になります。
治験責任医師は、参加するように招待された患者の数と比較して、研究に参加する意思のある適格な患者の数を評価します。
この結果の評価期間は、募集開始から最後の患者が含まれるまでで、約 1 年になります。
患者のアドヒアランス
時間枠:各患者の介入段階で、約 6 か月になります。
患者のアドヒアランスは、患者のドロップアウトの文書化によって評価されます。 詳細には、患者が治療中に研究を中止するかどうか (また、そうであれば、どの段階で) を記録します。
各患者の介入段階で、約 6 か月になります。
患者満足度
時間枠:患者が介入を完了した直後に、患者ごとに 1 回だけ評価されます。
アンケートによって評価されます (ワーキング アライアンス インベントリ - 短縮形が改訂されました)。 5 段階のリッカート スケールで評価された 12 項目の合計スコアが表示されます (12 から 60 の範囲)。 値が高いほど満足度が高くなります。
患者が介入を完了した直後に、患者ごとに 1 回だけ評価されます。
Therapist adherence
時間枠:Assessed during the intervention phase for each patient, i.e., within about 6 six months.
Using information of the therapy protocols of each participant, it will be assessed if the treatment sessions were done according to the treatment protocol.
Assessed during the intervention phase for each patient, i.e., within about 6 six months.

二次結果の測定

結果測定
メジャーの説明
時間枠
Levels of fatigue 1
時間枠:Assessed at three time points: before the intervention, immediately after the intervention and 3 months after the intervention
Assessed by a questionnaire, the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Module Measuring Cancer-Related Fatigue (EORTC QLQ-FA12). The questionnaire assesses the level of cancer-related fatigue. The sum score across all 12 items, rated on a 4-point Likert scale, will be reported (total range: 12-48). Higher values indicate higher levels of fatigue (i.e., higher values indicate a worse outcome).
Assessed at three time points: before the intervention, immediately after the intervention and 3 months after the intervention
Levels of fatigue 2
時間枠:Assessed at three time points: before the intervention, immediately after the intervention and 3 months after the intervention
Levels of fatigue will additionally assessed by a second questionnaire, the Checklist Individual Strength - Subscale Fatigue Severity. The scale assesses the level of cancer-related fatigue. The sum score across all 8 items, rated on a 7-point Likert scale, will be presented (total range: 8 - 56). Higher values indicate higher levels of fatigue (i.e., higher values indicate a worse outcome).
Assessed at three time points: before the intervention, immediately after the intervention and 3 months after the intervention
Global quality of life
時間枠:Assessed at three time points: before the intervention, immediately after the intervention and 3 months after the intervention
Global quality of Life will be assessed by the European Organisation for Research and Treatment of Cancer (EORTC), Quality of Life-questionnaire (EORTC QLQ-C30). Global quality of life is assessed in a 2-item subscale of the questionnaire, each rated on a 7-point-Likert scale (total range: 2-14). According to the questionnaire manual, however, the sum score of the two items will be linear-transformed to a 0-100 scale, with higher values indicating higher levels of quality of life (i.e., higher values indicate a better outcome).
Assessed at three time points: before the intervention, immediately after the intervention and 3 months after the intervention

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Anja Mehnert, Prof. Dr.、University of Leipzig
  • 主任研究者:Peter Borchmann, Prof. Dr.、University of Cologne

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2018年8月20日

一次修了 (実際)

2021年2月28日

研究の完了 (実際)

2021年3月15日

試験登録日

最初に提出

2018年8月24日

QC基準を満たした最初の提出物

2019年5月27日

最初の投稿 (実際)

2019年5月30日

学習記録の更新

投稿された最後の更新 (実際)

2021年4月28日

QC基準を満たした最後の更新が送信されました

2021年4月27日

最終確認日

2021年4月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

3
購読する